Apogee Therapeutics, Inc.
APGE evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Market Cap:
- $10.22B
- Lead Asset:
- apg273 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for APGE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APGE
Apogee Therapeutics, Inc. (APGE) is a clinical-stage biotechnology company developing optimized biologics for inflammatory and immunology indications, with lead candidate zumilokibart (APG777) in Phase 2 for atopic dermatitis and asthma.
Key risk: Clinical trial risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$10.22B
Cash Runway
—
Lead Asset
apg273 (Preclinical)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 4 clinical trials · 2 catalysts for Apogee Therapeutics, Inc..
Apogee Therapeutics, Inc. (APGE) is a clinical-stage biotechnology company developing optimized biologics for inflammatory and immunology indications, with lead candidate zumilokibart (APG777) in Phase 2 for atopic dermatitis and asthma.
- Lead product candidate zumilokibart (APG777) is in Phase 2 trials for moderate-to-severe atopic dermatitis and Phase 1b for mild-to-moderate asthma [sec_mda · as of 2026-08-10].
- Cash and cash equivalents were $105.6 million as of June 30, 2026, with net income of -$85.9 million for the same period [sec].
- The company reported a cash runway into the second half of 2028 as of January 2026 [sec · filed 2026-01-06].
- Multiple clinical data readouts are anticipated in 2026, including Phase 1b asthma and APEX Part A data in Q1 2026, APEX Part B in Q2 2026, and APG279 head-to-head against DUPIXENT in 2H 2026 [news · published 2025-11-10].
- Interim Phase 1 results for APG333 demonstrated a half-life of approximately 55 days and supported extended 3- and 6-month dosing intervals [news · published 2025-11-15].
What works
- Zumilokibart data supports quarterly (Q3M) and semi-annual (Q6M) dosing intervals, potentially offering less frequent dosing than current therapies [news · published 2026-03-24].
- The company has a strong cash runway into the second half of 2028, providing financial flexibility for ongoing and future trials [sec · filed 2026-01-06].
- Pipeline includes multiple programs (APG777, APG279, APG333) with several clinical readouts expected in 2026, indicating active development [news · published 2025-11-10].
What to weigh
- The company reported a net loss of $85.9 million for the six months ended June 30, 2026, reflecting significant ongoing R&D expenditure [sec].
- Clinical-stage biotech companies face inherent risks of trial failure, regulatory delays, or unfavorable data, which could impact timelines and financial position [sec_mda · as of 2026-03-02].
- Cash and cash equivalents decreased from $124.2 million (as of March 31, 2026) to $105.6 million (as of June 30, 2026), indicating a burn rate that may require future financing [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
Lead candidate zumilokibart (APG777) is in Phase 2 for atopic dermatitis and Phase 1b for asthma.
“A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis”
Catalysts · April 29, 2024
Cash runway into second half of 2028.
“The Company confirmed that it believes it has cash runway into the second half of 2028.”
SEC filings · January 6, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline — Topline results from the Phase 2 trial of zumilokibart in atopic dermatitis are expected, which will inform potential Phase 3 planning.
- 2027-12-31 · Phase2_Topline — Additional Phase 2 topline data may be disclosed, providing further efficacy and safety information.
Risks & what to watch (3)›
Key risks
- Clinical trial risk — Phase 2 and Phase 1b trials may fail to meet endpoints, delaying or halting programs [sec_mda · as of 2026-03-02].
- Cash burn rate — Cash decreased from $124.2M to $105.6M in three months, indicating a burn that may require future capital raises [sec_mda · as of 2026-08-10].
- Competitive landscape — Dupixent (DUPIXENT) is an established competitor; APG279 head-to-head data will be critical [news · published 2025-11-10].
What to watch
- Phase 2 topline results for zumilokibart in atopic dermatitis expected by end of 2026 [catalyst].
- APEX 52-week Part A data in AD anticipated in Q1 2026 [news · published 2025-11-10].
- APEX 16-week Part B data in AD in Q2 2026 [news · published 2025-11-10].
- APG279 Phase 1b head-to-head readout against DUPIXENT in AD in 2H 2026 [news · published 2025-11-10].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Apogee Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Apogee Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$86M
Lead: Phase 2
5 candidates
2 upcoming, next in ~78d
0 buys · 19 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
225
Total value held
$5.67B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 9,262,291 | $779.6M |
| venrock adviser, llc | 8,493,321 | $714.9M |
| wellington management group llp | 4,375,703 | $368.3M |
| blackrock, inc. | 4,085,651 | $343.9M |
| rtw investments, lp | 2,782,097 | $234.2M |
| vanguard capital management llc | 2,502,095 | $210.6M |
| janus henderson group plc | 2,360,596 | $198.8M |
| state street corp | 2,162,964 | $182.1M |
| driehaus capital management llc | 1,920,800 | $161.7M |
| perceptive advisors llc | 1,540,384 | $129.7M |
Showing top 10 of 225 institutional holders of Apogee Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 19.9%
- Days to cover
- 13.6
- Shares short
- 9,489,537
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
APGE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Apogee Therapeutics, Inc.?
Apogee Therapeutics, Inc. (APGE) is a clinical-stage biotechnology company developing optimized biologics for inflammatory and immunology indications, with lead candidate zumilokibart (APG777) in Phase 2 for atopic dermatitis and asthma.
What is Apogee Therapeutics, Inc.'s lead drug candidate?
Apogee Therapeutics, Inc.'s most advanced tracked candidate is apg273 (Preclinical) for COPD.
What is Apogee Therapeutics, Inc.'s next catalyst?
Apogee Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase2_Topline: Regulation FD Disclosure.: On May 27, 2026, Apogee Therapeutics, Inc. (the "Company")" — expected December 31, 2026.
Who is the CEO of Apogee Therapeutics, Inc.?
Dr. Michael Thomas Henderson M.D. is the chief executive officer of Apogee Therapeutics, Inc. (APGE).
Where is Apogee Therapeutics, Inc. headquartered?
Apogee Therapeutics, Inc. (APGE) is headquartered in San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.